An observational study in Cardiac Arrest, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2012-10-24.
Sponsored by University Hospital, Basel, Switzerland · Observational
Cardiac surgery including hypothermic cardiac arrest (HCA) commonly involves perioperative transfusion of allogeneic blood products which is associated with increased morbidity and mortality. In this retrospective analysis, the investigator aimed to evaluate the effect of a thromboelastometry-guided treatment algorithm promoting fibrinogen concentrate as first line hemostatic agent on the perioperative use of allogeneic blood products.
The investigators will analyze the data of patients undergoing elective and emergent surgical procedures involving the ascendent aorta and/or the aortic arch with the help of HCA from January 2009 to June 2011.
The investigators will collect and document baseline characteristics, the use of thromboelastometry, thromboelastometric data, and perioperative laboratory data. In addition, the investigators will evaluate perioperative bleeding from mediastinal drainages, perioperative use of blood and hemostatic products, and the adverse events within the hospitalisation including re-exploration, renal impairment, myocardial infarction, severe brain injury, and death.
984 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
This study's enrollment of 200 is close to the median of 196 across 394 observational studies indexed under Heart Arrest.
Browse Heart Arrest studies →University Hospital, Basel, Switzerland is the lead sponsor of 989 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
Transfusion of allogeneic blood products
Time frame: within 24 hours including surgery
Proportion of patients without allogeneic blood products
Time frame: 24 hours including surgery
Adverse events
Adverse events include: renal impairment (RIFLE criteria), stroke, severe neurologic impairment, myocardial infarction, death, re-exploration
Time frame: within 24 hours including surgery
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →